drugset / Trial / NCT02191189

Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males

NCT02191189

Phase 1 Completed 27 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to determine the absorption of Nevirapine from different regions of the Gastro Intestinal tract.

Timeline

Start
2005-05
Primary completion
2006-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nevirapine Small molecule 50 mg Oral

Indications

No indication recorded.